Table 1. Baseline characteristics.
| Characteristic | Patients (n=25) |
|---|---|
| Age (y) | 65 [42–74] |
| Sex, n (%) | |
| Male | 22 (88.0) |
| Female | 3 (12.0) |
| Smoking status, n (%) | |
| Yes | 9 (36.0) |
| No | 16 (64.0) |
| Histology, n (%) | |
| Adenocarcinoma | 5 (20.0) |
| Squamous cell cancer | 16 (64.0) |
| Large cell neuroendocrine carcinoma | 1 (4.0) |
| Adenosquamous carcinoma | 2 (8.0) |
| Sarcomatoid carcinoma | 1 (4.0) |
| Stage at diagnosis, n (%) | |
| IIB | 1 (4.0) |
| IIIA | 17 (68.0) |
| IIIB | 7 (28.0) |
| Tumor lesion size (mm) | 47 [21–80] |
| Clinical nodal status, n (%) | |
| N0 | 3 (12.0) |
| N1 | 1 (4.0) |
| N2 | 21 (84.0) |
| Treatment cycles, n (%) | |
| 2 cycles | 15 (60.0) |
| 3 cycles | 9 (36.0) |
| Unfinished# | 1 (4.0) |
Data are n (%) or median [IQR]. #, failure to complete the neoadjuvant therapy cycle due to severe treatment-related complications; IQR, interquartile range.